Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1999 Aug;52(8):555–568. doi: 10.1136/jcp.52.8.555

Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.

R J Michalides 1
PMCID: PMC500945  PMID: 10645224

Full text

PDF
555

Images in this article

555Image
on p.555
556Image
on p.556
559Image
on p.559
560Image
on p.560
562Image
on p.562
564Image
on p.564

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alevizopoulos K., Vlach J., Hennecke S., Amati B. Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J. 1997 Sep 1;16(17):5322–5333. doi: 10.1093/emboj/16.17.5322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Altucci L., Addeo R., Cicatiello L., Dauvois S., Parker M. G., Truss M., Beato M., Sica V., Bresciani F., Weisz A. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene. 1996 Jun 6;12(11):2315–2324. [PubMed] [Google Scholar]
  3. Arber N., Doki Y., Han E. K., Sgambato A., Zhou P., Kim N. H., Delohery T., Klein M. G., Holt P. R., Weinstein I. B. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res. 1997 Apr 15;57(8):1569–1574. [PubMed] [Google Scholar]
  4. Assoian R. K. Anchorage-dependent cell cycle progression. J Cell Biol. 1997 Jan 13;136(1):1–4. doi: 10.1083/jcb.136.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Banin S., Moyal L., Shieh S., Taya Y., Anderson C. W., Chessa L., Smorodinsky N. I., Prives C., Reiss Y., Shiloh Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 1998 Sep 11;281(5383):1674–1677. doi: 10.1126/science.281.5383.1674. [DOI] [PubMed] [Google Scholar]
  6. Barbieri F., Cagnoli M., Ragni N., Pedullà F., Foglia G., Alama A. Expression of cyclin D1 correlates with malignancy in human ovarian tumours. Br J Cancer. 1997;75(9):1263–1268. doi: 10.1038/bjc.1997.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bartek J., Bartkova J., Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol. 1996 Dec;8(6):805–814. doi: 10.1016/s0955-0674(96)80081-0. [DOI] [PubMed] [Google Scholar]
  8. Bartkova J., Lukas J., Strauss M., Bartek J. The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas. Int J Cancer. 1994 Aug 15;58(4):568–573. doi: 10.1002/ijc.2910580420. [DOI] [PubMed] [Google Scholar]
  9. Bates S., Parry D., Bonetta L., Vousden K., Dickson C., Peters G. Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene. 1994 Jun;9(6):1633–1640. [PubMed] [Google Scholar]
  10. Bates S., Phillips A. C., Clark P. A., Stott F., Peters G., Ludwig R. L., Vousden K. H. p14ARF links the tumour suppressors RB and p53. Nature. 1998 Sep 10;395(6698):124–125. doi: 10.1038/25867. [DOI] [PubMed] [Google Scholar]
  11. Beijersbergen R. L., Carlée L., Kerkhoven R. M., Bernards R. Regulation of the retinoblastoma protein-related p107 by G1 cyclin complexes. Genes Dev. 1995 Jun 1;9(11):1340–1353. doi: 10.1101/gad.9.11.1340. [DOI] [PubMed] [Google Scholar]
  12. Bernards R. E2F: a nodal point in cell cycle regulation. Biochim Biophys Acta. 1997 Dec 9;1333(3):M33–M40. doi: 10.1016/s0304-419x(97)00027-9. [DOI] [PubMed] [Google Scholar]
  13. Berx G., Cleton-Jansen A. M., Strumane K., de Leeuw W. J., Nollet F., van Roy F., Cornelisse C. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 1996 Nov 7;13(9):1919–1925. [PubMed] [Google Scholar]
  14. Betticher D. C., Thatcher N., Altermatt H. J., Hoban P., Ryder W. D., Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995 Sep 7;11(5):1005–1011. [PubMed] [Google Scholar]
  15. Blagosklonny M. V., El-Deiry W. S. Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer. 1998 Mar 16;75(6):933–940. doi: 10.1002/(sici)1097-0215(19980316)75:6<933::aid-ijc17>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  16. Blain S. W., Montalvo E., Massagué J. Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. J Biol Chem. 1997 Oct 10;272(41):25863–25872. doi: 10.1074/jbc.272.41.25863. [DOI] [PubMed] [Google Scholar]
  17. Bortner D. M., Rosenberg M. P. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol. 1997 Jan;17(1):453–459. doi: 10.1128/mcb.17.1.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Bottazzi M. E., Assoian R. K. The extracellular matrix and mitogenic growth factors control G1 phase cyclins and cyclin-dependent kinase inhibitors. Trends Cell Biol. 1997 Sep;7(9):348–352. doi: 10.1016/S0962-8924(97)01114-8. [DOI] [PubMed] [Google Scholar]
  19. Brown J. R., Nigh E., Lee R. J., Ye H., Thompson M. A., Saudou F., Pestell R. G., Greenberg M. E. Fos family members induce cell cycle entry by activating cyclin D1. Mol Cell Biol. 1998 Sep;18(9):5609–5619. doi: 10.1128/mcb.18.9.5609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Cahill D. P., Lengauer C., Yu J., Riggins G. J., Willson J. K., Markowitz S. D., Kinzler K. W., Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature. 1998 Mar 19;392(6673):300–303. doi: 10.1038/32688. [DOI] [PubMed] [Google Scholar]
  21. Califano J., van der Riet P., Westra W., Nawroz H., Clayman G., Piantadosi S., Corio R., Lee D., Greenberg B., Koch W. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 1996 Jun 1;56(11):2488–2492. [PubMed] [Google Scholar]
  22. Cardone M. H., Salvesen G. S., Widmann C., Johnson G., Frisch S. M. The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell. 1997 Jul 25;90(2):315–323. doi: 10.1016/s0092-8674(00)80339-6. [DOI] [PubMed] [Google Scholar]
  23. Chen J., Wu X., Lin J., Levine A. J. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol. 1996 May;16(5):2445–2452. doi: 10.1128/mcb.16.5.2445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Chin L., Pomerantz J., DePinho R. A. The INK4a/ARF tumor suppressor: one gene--two products--two pathways. Trends Biochem Sci. 1998 Aug;23(8):291–296. doi: 10.1016/s0968-0004(98)01236-5. [DOI] [PubMed] [Google Scholar]
  25. Clark E. A., King W. G., Brugge J. S., Symons M., Hynes R. O. Integrin-mediated signals regulated by members of the rho family of GTPases. J Cell Biol. 1998 Jul 27;142(2):573–586. doi: 10.1083/jcb.142.2.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Coleman K. G., Wautlet B. S., Morrissey D., Mulheron J., Sedman S. A., Brinkley P., Price S., Webster K. R. Identification of CDK4 sequences involved in cyclin D1 and p16 binding. J Biol Chem. 1997 Jul 25;272(30):18869–18874. doi: 10.1074/jbc.272.30.18869. [DOI] [PubMed] [Google Scholar]
  27. Connell-Crowley L., Elledge S. J., Harper J. W. G1 cyclin-dependent kinases are sufficient to initiate DNA synthesis in quiescent human fibroblasts. Curr Biol. 1998 Jan 1;8(1):65–68. doi: 10.1016/s0960-9822(98)70021-1. [DOI] [PubMed] [Google Scholar]
  28. Cote R. J., Shi Y., Groshen S., Feng A. C., Cordon-Cardo C., Skinner D., Lieskovosky G. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst. 1998 Jun 17;90(12):916–920. doi: 10.1093/jnci/90.12.916. [DOI] [PubMed] [Google Scholar]
  29. Courjal F., Louason G., Speiser P., Katsaros D., Zeillinger R., Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer. 1996 Aug 22;69(4):247–253. doi: 10.1002/(SICI)1097-0215(19960822)69:4<247::AID-IJC1>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  30. Diehl J. A., Sherr C. J. A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase. Mol Cell Biol. 1997 Dec;17(12):7362–7374. doi: 10.1128/mcb.17.12.7362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Diehl J. A., Zindy F., Sherr C. J. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 1997 Apr 15;11(8):957–972. doi: 10.1101/gad.11.8.957. [DOI] [PubMed] [Google Scholar]
  32. Doki Y., Imoto M., Han E. K., Sgambato A., Weinstein I. B. Increased expression of the P27KIP1 protein in human esophageal cancer cell lines that over-express cyclin D1. Carcinogenesis. 1997 Jun;18(6):1139–1148. doi: 10.1093/carcin/18.6.1139. [DOI] [PubMed] [Google Scholar]
  33. Dong Y., Walsh M. D., McGuckin M. A., Cummings M. C., Gabrielli B. G., Wright G. R., Hurst T., Khoo S. K., Parsons P. G. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer. 1997 Aug 22;74(4):407–415. doi: 10.1002/(sici)1097-0215(19970822)74:4<407::aid-ijc8>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  34. Donnellan R., Chetty R. Cyclin D1 and human neoplasia. Mol Pathol. 1998 Feb;51(1):1–7. doi: 10.1136/mp.51.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Dulić V., Stein G. H., Far D. F., Reed S. I. Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol Cell Biol. 1998 Jan;18(1):546–557. doi: 10.1128/mcb.18.1.546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Elledge S. J., Winston J., Harper J. W. A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis. Trends Cell Biol. 1996 Oct;6(10):388–392. doi: 10.1016/0962-8924(96)10030-1. [DOI] [PubMed] [Google Scholar]
  37. Esposito V., Baldi A., De Luca A., Groger A. M., Loda M., Giordano G. G., Caputi M., Baldi F., Pagano M., Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997 Aug 15;57(16):3381–3385. [PubMed] [Google Scholar]
  38. Evan G., Littlewood T. A matter of life and cell death. Science. 1998 Aug 28;281(5381):1317–1322. doi: 10.1126/science.281.5381.1317. [DOI] [PubMed] [Google Scholar]
  39. Falette N., Paperin M. P., Treilleux I., Gratadour A. C., Peloux N., Mignotte H., Tooke N., Löfman E., Inganäs M., Bremond A. Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res. 1998 Apr 1;58(7):1451–1455. [PubMed] [Google Scholar]
  40. Fan J., Bertino J. R. Functional roles of E2F in cell cycle regulation. Oncogene. 1997 Mar 13;14(10):1191–1200. doi: 10.1038/sj.onc.1200940. [DOI] [PubMed] [Google Scholar]
  41. Fang F., Orend G., Watanabe N., Hunter T., Ruoslahti E. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science. 1996 Jan 26;271(5248):499–502. doi: 10.1126/science.271.5248.499. [DOI] [PubMed] [Google Scholar]
  42. Fantl V., Stamp G., Andrews A., Rosewell I., Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 1995 Oct 1;9(19):2364–2372. doi: 10.1101/gad.9.19.2364. [DOI] [PubMed] [Google Scholar]
  43. Fearon E. R. Human cancer syndromes: clues to the origin and nature of cancer. Science. 1997 Nov 7;278(5340):1043–1050. doi: 10.1126/science.278.5340.1043. [DOI] [PubMed] [Google Scholar]
  44. Fredersdorf S., Burns J., Milne A. M., Packham G., Fallis L., Gillett C. E., Royds J. A., Peston D., Hall P. A., Hanby A. M. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6380–6385. doi: 10.1073/pnas.94.12.6380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Frisch S. M., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994 Feb;124(4):619–626. doi: 10.1083/jcb.124.4.619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Gansauge S., Gansauge F., Ramadani M., Stobbe H., Rau B., Harada N., Beger H. G. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. 1997 May 1;57(9):1634–1637. [PubMed] [Google Scholar]
  47. Gazzeri S., Della Valle V., Chaussade L., Brambilla C., Larsen C. J., Brambilla E. The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. Cancer Res. 1998 Sep 1;58(17):3926–3931. [PubMed] [Google Scholar]
  48. Geradts J., Kratzke R. A., Niehans G. A., Lincoln C. E. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res. 1995 Dec 15;55(24):6006–6011. [PubMed] [Google Scholar]
  49. Geradts J., Wilson P. A. High frequency of aberrant p16(INK4A) expression in human breast cancer. Am J Pathol. 1996 Jul;149(1):15–20. [PMC free article] [PubMed] [Google Scholar]
  50. Graeber T. G., Osmanian C., Jacks T., Housman D. E., Koch C. J., Lowe S. W., Giaccia A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996 Jan 4;379(6560):88–91. doi: 10.1038/379088a0. [DOI] [PubMed] [Google Scholar]
  51. Guadagno T. M., Newport J. W. Cdk2 kinase is required for entry into mitosis as a positive regulator of Cdc2-cyclin B kinase activity. Cell. 1996 Jan 12;84(1):73–82. doi: 10.1016/s0092-8674(00)80994-0. [DOI] [PubMed] [Google Scholar]
  52. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67–108. doi: 10.1016/s0065-230x(08)60352-8. [DOI] [PubMed] [Google Scholar]
  53. Han E. K., Begemann M., Sgambato A., Soh J. W., Doki Y., Xing W. Q., Liu W., Weinstein I. B. Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1, inhibits growth, and enhances apoptosis. Cell Growth Differ. 1996 Jun;7(6):699–710. [PubMed] [Google Scholar]
  54. Harper J. W. Cyclin dependent kinase inhibitors. Cancer Surv. 1997;29:91–107. [PubMed] [Google Scholar]
  55. Harper J. W., Elledge S. J., Keyomarsi K., Dynlacht B., Tsai L. H., Zhang P., Dobrowolski S., Bai C., Connell-Crowley L., Swindell E. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell. 1995 Apr;6(4):387–400. doi: 10.1091/mbc.6.4.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Hashemolhosseini S., Nagamine Y., Morley S. J., Desrivières S., Mercep L., Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem. 1998 Jun 5;273(23):14424–14429. doi: 10.1074/jbc.273.23.14424. [DOI] [PubMed] [Google Scholar]
  57. Hawkins D. S., Demers G. W., Galloway D. A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 1996 Feb 15;56(4):892–898. [PubMed] [Google Scholar]
  58. He J., Allen J. R., Collins V. P., Allalunis-Turner M. J., Godbout R., Day R. S., 3rd, James C. D. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 1994 Nov 15;54(22):5804–5807. [PubMed] [Google Scholar]
  59. He T. C., Sparks A. B., Rago C., Hermeking H., Zawel L., da Costa L. T., Morin P. J., Vogelstein B., Kinzler K. W. Identification of c-MYC as a target of the APC pathway. Science. 1998 Sep 4;281(5382):1509–1512. doi: 10.1126/science.281.5382.1509. [DOI] [PubMed] [Google Scholar]
  60. Herber B., Truss M., Beato M., Müller R. Inducible regulatory elements in the human cyclin D1 promoter. Oncogene. 1994 Jul;9(7):2105–2107. [PubMed] [Google Scholar]
  61. Herrera R. E., Sah V. P., Williams B. O., Mäkelä T. P., Weinberg R. A., Jacks T. Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol Cell Biol. 1996 May;16(5):2402–2407. doi: 10.1128/mcb.16.5.2402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Hiebert S. W., Packham G., Strom D. K., Haffner R., Oren M., Zambetti G., Cleveland J. L. E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell Biol. 1995 Dec;15(12):6864–6874. doi: 10.1128/mcb.15.12.6864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Hinds P. W., Dowdy S. F., Eaton E. N., Arnold A., Weinberg R. A. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):709–713. doi: 10.1073/pnas.91.2.709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Hirai H., Sherr C. J. Interaction of D-type cyclins with a novel myb-like transcription factor, DMP1. Mol Cell Biol. 1996 Nov;16(11):6457–6467. doi: 10.1128/mcb.16.11.6457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Hiyama H., Iavarone A., LaBaer J., Reeves S. A. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene. 1997 May 29;14(21):2533–2542. doi: 10.1038/sj.onc.1201080. [DOI] [PubMed] [Google Scholar]
  66. Hiyama H., Iavarone A., Reeves S. A. Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F. Oncogene. 1998 Mar 26;16(12):1513–1523. doi: 10.1038/sj.onc.1201667. [DOI] [PubMed] [Google Scholar]
  67. Hosokawa Y., Suzuki R., Joh T., Maeda Y., Nakamura S., Kodera Y., Arnold A., Seto M. A small deletion in the 3'-untranslated region of the cyclin D1/PRAD1/bcl-1 oncogene in a patient with chronic lymphocytic leukemia. Int J Cancer. 1998 Jun 10;76(6):791–796. doi: 10.1002/(sici)1097-0215(19980610)76:6<791::aid-ijc4>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  68. Houldsworth J., Reuter V., Bosl G. J., Chaganti R. S. Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis. Cell Growth Differ. 1997 Mar;8(3):293–299. [PubMed] [Google Scholar]
  69. Hoyt M. A. Eliminating all obstacles: regulated proteolysis in the eukaryotic cell cycle. Cell. 1997 Oct 17;91(2):149–151. doi: 10.1016/s0092-8674(00)80396-7. [DOI] [PubMed] [Google Scholar]
  70. Hui R., Cornish A. L., McClelland R. A., Robertson J. F., Blamey R. W., Musgrove E. A., Nicholson R. I., Sutherland R. L. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res. 1996 Jun;2(6):923–928. [PubMed] [Google Scholar]
  71. Hunter T. Oncoprotein networks. Cell. 1997 Feb 7;88(3):333–346. doi: 10.1016/s0092-8674(00)81872-3. [DOI] [PubMed] [Google Scholar]
  72. Hunter T., Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 1994 Nov 18;79(4):573–582. doi: 10.1016/0092-8674(94)90543-6. [DOI] [PubMed] [Google Scholar]
  73. Hurford R. K., Jr, Cobrinik D., Lee M. H., Dyson N. pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev. 1997 Jun 1;11(11):1447–1463. doi: 10.1101/gad.11.11.1447. [DOI] [PubMed] [Google Scholar]
  74. Ishikawa T., Furihata M., Ohtsuki Y., Murakami H., Inoue A., Ogoshi S. Cyclin D1 overexpression related to retinoblastoma protein expression as a prognostic marker in human oesophageal squamous cell carcinoma. Br J Cancer. 1998;77(1):92–97. doi: 10.1038/bjc.1998.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Jackman M. R., Pines J. N. Cyclins and the G2/M transition. Cancer Surv. 1997;29:47–73. [PubMed] [Google Scholar]
  76. Jacks T., Fazeli A., Schmitt E. M., Bronson R. T., Goodell M. A., Weinberg R. A. Effects of an Rb mutation in the mouse. Nature. 1992 Sep 24;359(6393):295–300. doi: 10.1038/359295a0. [DOI] [PubMed] [Google Scholar]
  77. Jares P., Rey M. J., Fernández P. L., Campo E., Nadal A., Muñoz M., Mallofré C., Muntané J., Nayach I., Estapé J. Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlation with tumour proliferation and oestrogen receptor status. J Pathol. 1997 Jun;182(2):160–166. doi: 10.1002/(SICI)1096-9896(199706)182:2<160::AID-PATH814>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  78. Johnson D. G., Schwarz J. K., Cress W. D., Nevins J. R. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 1993 Sep 23;365(6444):349–352. doi: 10.1038/365349a0. [DOI] [PubMed] [Google Scholar]
  79. Kallakury B. V., Sheehan C. E., Ambros R. A., Fisher H. A., Kaufman R. P., Jr, Ross J. S. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer. 1997 Aug 15;80(4):753–763. doi: 10.1002/(sici)1097-0142(19970815)80:4<753::aid-cncr15>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  80. Kamijo T., Zindy F., Roussel M. F., Quelle D. E., Downing J. R., Ashmun R. A., Grosveld G., Sherr C. J. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 1997 Nov 28;91(5):649–659. doi: 10.1016/s0092-8674(00)80452-3. [DOI] [PubMed] [Google Scholar]
  81. Keyomarsi K., O'Leary N., Molnar G., Lees E., Fingert H. J., Pardee A. B. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res. 1994 Jan 15;54(2):380–385. [PubMed] [Google Scholar]
  82. Kitagawa M., Higashi H., Jung H. K., Suzuki-Takahashi I., Ikeda M., Tamai K., Kato J., Segawa K., Yoshida E., Nishimura S. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J. 1996 Dec 16;15(24):7060–7069. [PMC free article] [PubMed] [Google Scholar]
  83. Kovach J. S., Hartmann A., Blaszyk H., Cunningham J., Schaid D., Sommer S. S. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1093–1096. doi: 10.1073/pnas.93.3.1093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Krek W., Xu G., Livingston D. M. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell. 1995 Dec 29;83(7):1149–1158. doi: 10.1016/0092-8674(95)90141-8. [DOI] [PubMed] [Google Scholar]
  85. LaBaer J., Garrett M. D., Stevenson L. F., Slingerland J. M., Sandhu C., Chou H. S., Fattaey A., Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997 Apr 1;11(7):847–862. doi: 10.1101/gad.11.7.847. [DOI] [PubMed] [Google Scholar]
  86. Lane D. P. Cancer. A death in the life of p53. Nature. 1993 Apr 29;362(6423):786–787. doi: 10.1038/362786a0. [DOI] [PubMed] [Google Scholar]
  87. Lane D. Awakening angels. Nature. 1998 Aug 13;394(6694):616–617. doi: 10.1038/29166. [DOI] [PubMed] [Google Scholar]
  88. Lengauer C., Kinzler K. W., Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997 Apr 10;386(6625):623–627. doi: 10.1038/386623a0. [DOI] [PubMed] [Google Scholar]
  89. Levine A. J. p53, the cellular gatekeeper for growth and division. Cell. 1997 Feb 7;88(3):323–331. doi: 10.1016/s0092-8674(00)81871-1. [DOI] [PubMed] [Google Scholar]
  90. Li Y., Nichols M. A., Shay J. W., Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 1994 Dec 1;54(23):6078–6082. [PubMed] [Google Scholar]
  91. Lipponen P. K., Liukkonen T. J. Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancer. J Cancer Res Clin Oncol. 1995;121(1):44–50. doi: 10.1007/BF01202728. [DOI] [PubMed] [Google Scholar]
  92. Liu B., Parsons R., Papadopoulos N., Nicolaides N. C., Lynch H. T., Watson P., Jass J. R., Dunlop M., Wyllie A., Peltomäki P. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med. 1996 Feb;2(2):169–174. doi: 10.1038/nm0296-169. [DOI] [PubMed] [Google Scholar]
  93. Liu Y., Martindale J. L., Gorospe M., Holbrook N. J. Regulation of p21WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res. 1996 Jan 1;56(1):31–35. [PubMed] [Google Scholar]
  94. Lovec H., Grzeschiczek A., Kowalski M. B., Möröy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994 Aug 1;13(15):3487–3495. doi: 10.1002/j.1460-2075.1994.tb06655.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Lukas J., Bartkova J., Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol. 1996 Dec;16(12):6917–6925. doi: 10.1128/mcb.16.12.6917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Lukas J., Bartkova J., Rohde M., Strauss M., Bartek J. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol. 1995 May;15(5):2600–2611. doi: 10.1128/mcb.15.5.2600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Lukas J., Parry D., Aagaard L., Mann D. J., Bartkova J., Strauss M., Peters G., Bartek J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature. 1995 Jun 8;375(6531):503–506. doi: 10.1038/375503a0. [DOI] [PubMed] [Google Scholar]
  98. Macleod K. F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., Vogelstein B., Jacks T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 1995 Apr 15;9(8):935–944. doi: 10.1101/gad.9.8.935. [DOI] [PubMed] [Google Scholar]
  99. Maeda K., Chung Y., Kang S., Ogawa M., Onoda N., Nishiguchi Y., Ikehara T., Nakata B., Okuno M., Sowa M. Cyclin D1 overexpression and prognosis in colorectal adenocarcinoma. Oncology. 1998 Mar-Apr;55(2):145–151. doi: 10.1159/000011849. [DOI] [PubMed] [Google Scholar]
  100. Massagué J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753–791. doi: 10.1146/annurev.biochem.67.1.753. [DOI] [PubMed] [Google Scholar]
  101. Masuda M., Hirakawa N., Nakashima T., Kuratomi Y., Komiyama S. Cyclin D1 overexpression in primary hypopharyngeal carcinomas. Cancer. 1996 Aug 1;78(3):390–395. doi: 10.1002/(SICI)1097-0142(19960801)78:3<390::AID-CNCR2>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  102. McIntosh G. G., Anderson J. J., Milton I., Steward M., Parr A. H., Thomas M. D., Henry J. A., Angus B., Lennard T. W., Horne C. H. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene. 1995 Sep 7;11(5):885–891. [PubMed] [Google Scholar]
  103. Meredith S. D., Levine P. A., Burns J. A., Gaffey M. J., Boyd J. C., Weiss L. M., Erickson N. L., Williams M. E. Chromosome 11q13 amplification in head and neck squamous cell carcinoma. Association with poor prognosis. Arch Otolaryngol Head Neck Surg. 1995 Jul;121(7):790–794. doi: 10.1001/archotol.1995.01890070076016. [DOI] [PubMed] [Google Scholar]
  104. Michalides R. J., van Veelen N. M., Kristel P. M., Hart A. A., Loftus B. M., Hilgers F. J., Balm A. J. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1997 May;123(5):497–502. doi: 10.1001/archotol.1997.01900050045005. [DOI] [PubMed] [Google Scholar]
  105. Michalides R., Hageman P., van Tinteren H., Houben L., Wientjens E., Klompmaker R., Peterse J. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer. 1996 Mar;73(6):728–734. doi: 10.1038/bjc.1996.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Michalides R., van Veelen N., Hart A., Loftus B., Wientjens E., Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 1995 Mar 1;55(5):975–978. [PubMed] [Google Scholar]
  107. Moberg K., Starz M. A., Lees J. A. E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol Cell Biol. 1996 Apr;16(4):1436–1449. doi: 10.1128/mcb.16.4.1436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Morgan D. O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 1997;13:261–291. doi: 10.1146/annurev.cellbio.13.1.261. [DOI] [PubMed] [Google Scholar]
  109. Morin P. J., Sparks A. B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K. W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997 Mar 21;275(5307):1787–1790. doi: 10.1126/science.275.5307.1787. [DOI] [PubMed] [Google Scholar]
  110. Mueller A., Odze R., Jenkins T. D., Shahsesfaei A., Nakagawa H., Inomoto T., Rustgi A. K. A transgenic mouse model with cyclin D1 overexpression results in cell cycle, epidermal growth factor receptor, and p53 abnormalities. Cancer Res. 1997 Dec 15;57(24):5542–5549. [PubMed] [Google Scholar]
  111. Müller D., Bouchard C., Rudolph B., Steiner P., Stuckmann I., Saffrich R., Ansorge W., Huttner W., Eilers M. Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes. Oncogene. 1997 Nov 20;15(21):2561–2576. doi: 10.1038/sj.onc.1201440. [DOI] [PubMed] [Google Scholar]
  112. Müller H., Lukas J., Schneider A., Warthoe P., Bartek J., Eilers M., Strauss M. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2945–2949. doi: 10.1073/pnas.91.8.2945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Nadal A., Jares P., Cazorla M., Fernández P. L., Sanjuan X., Hernandez L., Pinyol M., Aldea M., Mallofré C., Muntané J. p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. J Pathol. 1997 Oct;183(2):156–163. doi: 10.1002/(SICI)1096-9896(199710)183:2<156::AID-PATH908>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  114. Naka T., Kobayashi M., Ashida K., Toyota N., Kaneko T., Kaibara N. Aberrant p16INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer. Int J Oncol. 1998 May;12(5):1111–1116. doi: 10.3892/ijo.12.5.1111. [DOI] [PubMed] [Google Scholar]
  115. Neuman E., Ladha M. H., Lin N., Upton T. M., Miller S. J., DiRenzo J., Pestell R. G., Hinds P. W., Dowdy S. F., Brown M. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol. 1997 Sep;17(9):5338–5347. doi: 10.1128/mcb.17.9.5338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Niculescu A. B., 3rd, Chen X., Smeets M., Hengst L., Prives C., Reed S. I. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol. 1998 Jan;18(1):629–643. doi: 10.1128/mcb.18.1.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. Nielsen N. H., Emdin S. O., Cajander J., Landberg G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene. 1997 Jan 23;14(3):295–304. doi: 10.1038/sj.onc.1200833. [DOI] [PubMed] [Google Scholar]
  118. Nogueira C. P., Dolan R. W., Gooey J., Byahatti S., Vaughan C. W., Fuleihan N. S., Grillone G., Baker E., Domanowski G. Inactivation of p53 and amplification of cyclin D1 correlate with clinical outcome in head and neck cancer. Laryngoscope. 1998 Mar;108(3):345–350. doi: 10.1097/00005537-199803000-00007. [DOI] [PubMed] [Google Scholar]
  119. O'Connor P. M. Mammalian G1 and G2 phase checkpoints. Cancer Surv. 1997;29:151–182. [PubMed] [Google Scholar]
  120. Ohtani K., DeGregori J., Nevins J. R. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12146–12150. doi: 10.1073/pnas.92.26.12146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Ohtsubo M., Theodoras A. M., Schumacher J., Roberts J. M., Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol. 1995 May;15(5):2612–2624. doi: 10.1128/mcb.15.5.2612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Okamoto A., Hussain S. P., Hagiwara K., Spillare E. A., Rusin M. R., Demetrick D. J., Serrano M., Hannon G. J., Shiseki M., Zariwala M. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res. 1995 Apr 1;55(7):1448–1451. [PubMed] [Google Scholar]
  123. Olshan A. F., Weissler M. C., Pei H., Conway K., Anderson S., Fried D. B., Yarbrough W. G. Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogene. 1997 Feb 20;14(7):811–818. doi: 10.1038/sj.onc.1200892. [DOI] [PubMed] [Google Scholar]
  124. Oyama T., Kashiwabara K., Yoshimoto K., Arnold A., Koerner F. Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res. 1998 Jul 1;58(13):2876–2880. [PubMed] [Google Scholar]
  125. Palmero I., Pantoja C., Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature. 1998 Sep 10;395(6698):125–126. doi: 10.1038/25870. [DOI] [PubMed] [Google Scholar]
  126. Pardee A. B. G1 events and regulation of cell proliferation. Science. 1989 Nov 3;246(4930):603–608. doi: 10.1126/science.2683075. [DOI] [PubMed] [Google Scholar]
  127. Pardo F. S., Su M., Borek C. Cyclin D1 induced apoptosis maintains the integrity of the G1/S checkpoint following ionizing radiation irradiation. Somat Cell Mol Genet. 1996 Mar;22(2):135–144. doi: 10.1007/BF02369903. [DOI] [PubMed] [Google Scholar]
  128. Parry D., Bates S., Mann D. J., Peters G. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J. 1995 Feb 1;14(3):503–511. doi: 10.1002/j.1460-2075.1995.tb07026.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Phillips A. C., Bates S., Ryan K. M., Helin K., Vousden K. H. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev. 1997 Jul 15;11(14):1853–1863. doi: 10.1101/gad.11.14.1853. [DOI] [PubMed] [Google Scholar]
  130. Planas-Silva M. D., Weinberg R. A. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol. 1997 Jul;17(7):4059–4069. doi: 10.1128/mcb.17.7.4059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Poon R. Y., Hunter T. Cell regulation. Innocent bystanders or chosen collaborators? Curr Biol. 1995 Nov 1;5(11):1243–1247. doi: 10.1016/s0960-9822(95)00248-x. [DOI] [PubMed] [Google Scholar]
  132. Porter P. L., Malone K. E., Heagerty P. J., Alexander G. M., Gatti L. A., Firpo E. J., Daling J. R., Roberts J. M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997 Feb;3(2):222–225. doi: 10.1038/nm0297-222. [DOI] [PubMed] [Google Scholar]
  133. Prall O. W., Sarcevic B., Musgrove E. A., Watts C. K., Sutherland R. L. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem. 1997 Apr 18;272(16):10882–10894. doi: 10.1074/jbc.272.16.10882. [DOI] [PubMed] [Google Scholar]
  134. Qin X. Q., Livingston D. M., Kaelin W. G., Jr, Adams P. D. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10918–10922. doi: 10.1073/pnas.91.23.10918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  135. Quelle D. E., Ashmun R. A., Shurtleff S. A., Kato J. Y., Bar-Sagi D., Roussel M. F., Sherr C. J. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 1993 Aug;7(8):1559–1571. doi: 10.1101/gad.7.8.1559. [DOI] [PubMed] [Google Scholar]
  136. Rao S. S., Chu C., Kohtz D. S. Ectopic expression of cyclin D1 prevents activation of gene transcription by myogenic basic helix-loop-helix regulators. Mol Cell Biol. 1994 Aug;14(8):5259–5267. doi: 10.1128/mcb.14.8.5259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Reed A. L., Califano J., Cairns P., Westra W. H., Jones R. M., Koch W., Ahrendt S., Eby Y., Sewell D., Nawroz H. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 1996 Aug 15;56(16):3630–3633. [PubMed] [Google Scholar]
  138. Resnitzky D. Ectopic expression of cyclin D1 but not cyclin E induces anchorage-independent cell cycle progression. Mol Cell Biol. 1997 Sep;17(9):5640–5647. doi: 10.1128/mcb.17.9.5640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  139. Resnitzky D., Reed S. I. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol. 1995 Jul;15(7):3463–3469. doi: 10.1128/mcb.15.7.3463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. Rey M. J., Fernández P. L., Jares P., Muñoz M., Nadal A., Peiró N., Nayach I., Mallofré C., Muntané J., Campo E. p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J Pathol. 1998 Mar;184(3):265–271. doi: 10.1002/(SICI)1096-9896(199803)184:3<265::AID-PATH8>3.0.CO;2-8. [DOI] [PubMed] [Google Scholar]
  141. Righetti S. C., Della Torre G., Pilotti S., Ménard S., Ottone F., Colnaghi M. I., Pierotti M. A., Lavarino C., Cornarotti M., Oriana S. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 1996 Feb 15;56(4):689–693. [PubMed] [Google Scholar]
  142. Robles A. I., Larcher F., Whalin R. B., Murillas R., Richie E., Gimenez-Conti I. B., Jorcano J. L., Conti C. J. Expression of cyclin D1 in epithelial tissues of transgenic mice results in epidermal hyperproliferation and severe thymic hyperplasia. Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7634–7638. doi: 10.1073/pnas.93.15.7634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  143. Romanowski P., Madine M. A. Mechanisms restricting DNA replication to once per cell cycle: the role of Cdc6p and ORC. Trends Cell Biol. 1997 Jan;7(1):9–10. doi: 10.1016/S0962-8924(97)30077-4. [DOI] [PubMed] [Google Scholar]
  144. Roussel M. F. Key effectors of signal transduction and G1 progression. Adv Cancer Res. 1998;74:1–24. doi: 10.1016/s0065-230x(08)60763-0. [DOI] [PubMed] [Google Scholar]
  145. Rusch V., Klimstra D., Venkatraman E., Oliver J., Martini N., Gralla R., Kris M., Dmitrovsky E. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 1995 Nov 1;55(21):5038–5042. [PubMed] [Google Scholar]
  146. Sandhu C., Garbe J., Bhattacharya N., Daksis J., Pan C. H., Yaswen P., Koh J., Slingerland J. M., Stampfer M. R. Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Mol Cell Biol. 1997 May;17(5):2458–2467. doi: 10.1128/mcb.17.5.2458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  147. Sawa H., Ohshima T. A., Ukita H., Murakami H., Chiba Y., Kamada H., Hara M., Saito I. Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene. 1998 Apr 2;16(13):1701–1712. doi: 10.1038/sj.onc.1201691. [DOI] [PubMed] [Google Scholar]
  148. Schlaepfer D. D., Hanks S. K., Hunter T., van der Geer P. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature. 1994 Dec 22;372(6508):786–791. doi: 10.1038/372786a0. [DOI] [PubMed] [Google Scholar]
  149. Schmidt E. E., Ichimura K., Reifenberger G., Collins V. P. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 1994 Dec 15;54(24):6321–6324. [PubMed] [Google Scholar]
  150. Schrier P. I., Bernards R., Vaessen R. T., Houweling A., van der Eb A. J. Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. 1983 Oct 27-Nov 2Nature. 305(5937):771–775. doi: 10.1038/305771a0. [DOI] [PubMed] [Google Scholar]
  151. Schulze A., Zerfass K., Spitkovsky D., Middendorp S., Bergès J., Helin K., Jansen-Dürr P., Henglein B. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11264–11268. doi: 10.1073/pnas.92.24.11264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  152. Schuuring E., Verhoeven E., van Tinteren H., Peterse J. L., Nunnink B., Thunnissen F. B., Devilee P., Cornelisse C. J., van de Vijver M. J., Mooi W. J. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res. 1992 Oct 1;52(19):5229–5234. [PubMed] [Google Scholar]
  153. Schwab M. Amplification of oncogenes in human cancer cells. Bioessays. 1998 Jun;20(6):473–479. doi: 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  154. Scott K. A., Walker R. A. Lack of cyclin E immunoreactivity in non-malignant breast and association with proliferation in breast cancer. Br J Cancer. 1997;76(10):1288–1292. doi: 10.1038/bjc.1997.550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  155. Seghezzi W., Chua K., Shanahan F., Gozani O., Reed R., Lees E. Cyclin E associates with components of the pre-mRNA splicing machinery in mammalian cells. Mol Cell Biol. 1998 Aug;18(8):4526–4536. doi: 10.1128/mcb.18.8.4526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  156. Serrano M., Lin A. W., McCurrach M. E., Beach D., Lowe S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997 Mar 7;88(5):593–602. doi: 10.1016/s0092-8674(00)81902-9. [DOI] [PubMed] [Google Scholar]
  157. Seshadri R., Lee C. S., Hui R., McCaul K., Horsfall D. J., Sutherland R. L. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res. 1996 Jul;2(7):1177–1184. [PubMed] [Google Scholar]
  158. Shan B., Durfee T., Lee W. H. Disruption of RB/E2F-1 interaction by single point mutations in E2F-1 enhances S-phase entry and apoptosis. Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):679–684. doi: 10.1073/pnas.93.2.679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  159. Shapiro G. I., Edwards C. D., Ewen M. E., Rollins B. J. p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol Cell Biol. 1998 Jan;18(1):378–387. doi: 10.1128/mcb.18.1.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  160. Sherr C. J. Cancer cell cycles. Science. 1996 Dec 6;274(5293):1672–1677. doi: 10.1126/science.274.5293.1672. [DOI] [PubMed] [Google Scholar]
  161. Sherr C. J. D-type cyclins. Trends Biochem Sci. 1995 May;20(5):187–190. doi: 10.1016/s0968-0004(00)89005-2. [DOI] [PubMed] [Google Scholar]
  162. Sherr C. J. G1 phase progression: cycling on cue. Cell. 1994 Nov 18;79(4):551–555. doi: 10.1016/0092-8674(94)90540-1. [DOI] [PubMed] [Google Scholar]
  163. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995 May 15;9(10):1149–1163. doi: 10.1101/gad.9.10.1149. [DOI] [PubMed] [Google Scholar]
  164. Shin K. Y., Kong G., Kim W. S., Lee T. Y., Woo Y. N., Lee J. D. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer. 1997;75(12):1788–1792. doi: 10.1038/bjc.1997.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  165. Sicinski P., Donaher J. L., Geng Y., Parker S. B., Gardner H., Park M. Y., Robker R. L., Richards J. S., McGinnis L. K., Biggers J. D. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature. 1996 Dec 5;384(6608):470–474. doi: 10.1038/384470a0. [DOI] [PubMed] [Google Scholar]
  166. Sicinski P., Donaher J. L., Parker S. B., Li T., Fazeli A., Gardner H., Haslam S. Z., Bronson R. T., Elledge S. J., Weinberg R. A. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell. 1995 Aug 25;82(4):621–630. doi: 10.1016/0092-8674(95)90034-9. [DOI] [PubMed] [Google Scholar]
  167. Simpson J. F., Quan D. E., O'Malley F., Odom-Maryon T., Clarke P. E. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am J Pathol. 1997 Jul;151(1):161–168. [PMC free article] [PubMed] [Google Scholar]
  168. Sjögren S., Inganäs M., Norberg T., Lindgren A., Nordgren H., Holmberg L., Bergh J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996 Feb 21;88(3-4):173–182. doi: 10.1093/jnci/88.3-4.173. [DOI] [PubMed] [Google Scholar]
  169. Snijders P. J., van Duin M., Walboomers J. M., Steenbergen R. D., Risse E. K., Helmerhorst T. J., Verheijen R. H., Meijer C. J. Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Res. 1998 Sep 1;58(17):3812–3818. [PubMed] [Google Scholar]
  170. Sofer-Levi Y., Resnitzky D. Apoptosis induced by ectopic expression of cyclin D1 but not cyclin E. Oncogene. 1996 Dec 5;13(11):2431–2437. [PubMed] [Google Scholar]
  171. St Croix B., Sheehan C., Rak J. W., Flørenes V. A., Slingerland J. M., Kerbel R. S. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol. 1998 Jul 27;142(2):557–571. doi: 10.1083/jcb.142.2.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  172. Swerdlow S. H., Yang W. I., Zukerberg L. R., Harris N. L., Arnold A., Williams M. E. Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCL1/cyclin D1 gene. Hum Pathol. 1995 Sep;26(9):999–1004. doi: 10.1016/0046-8177(95)90090-x. [DOI] [PubMed] [Google Scholar]
  173. Taga S., Osaki T., Ohgami A., Imoto H., Yoshimatsu T., Yoshino I., Yano K., Nakanishi R., Ichiyoshi Y., Yasumoto K. Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma. Cancer. 1997 Aug 1;80(3):389–395. doi: 10.1002/(sici)1097-0142(19970801)80:3<389::aid-cncr6>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  174. Takes R. P., Baatenburg de Jong R. J., Schuuring E., Hermans J., Vis A. A., Litvinov S. V., van Krieken J. H. Markers for assessment of nodal metastasis in laryngeal carcinoma. Arch Otolaryngol Head Neck Surg. 1997 Apr;123(4):412–419. doi: 10.1001/archotol.1997.01900040048008. [DOI] [PubMed] [Google Scholar]
  175. Tan P., Cady B., Wanner M., Worland P., Cukor B., Magi-Galluzzi C., Lavin P., Draetta G., Pagano M., Loda M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res. 1997 Apr 1;57(7):1259–1263. [PubMed] [Google Scholar]
  176. Tang R., Cheng A. J., Wang J. Y., Wang T. C. Close correlation between telomerase expression and adenomatous polyp progression in multistep colorectal carcinogenesis. Cancer Res. 1998 Sep 15;58(18):4052–4054. [PubMed] [Google Scholar]
  177. Tishler R. B., Lamppu D. M., Park S., Price B. D. Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res. 1995 Dec 15;55(24):6021–6025. [PubMed] [Google Scholar]
  178. Trowbridge J. M., Rogatsky I., Garabedian M. J. Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10132–10137. doi: 10.1073/pnas.94.19.10132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  179. Tsao H., Benoit E., Sober A. J., Thiele C., Haluska F. G. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. Cancer Res. 1998 Jan 1;58(1):109–113. [PubMed] [Google Scholar]
  180. Tsihlias J., Kapusta L. R., DeBoer G., Morava-Protzner I., Zbieranowski I., Bhattacharya N., Catzavelos G. C., Klotz L. H., Slingerland J. M. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 1998 Feb 1;58(3):542–548. [PubMed] [Google Scholar]
  181. Tsuda H., Hirohashi S., Shimosato Y., Hirota T., Tsugane S., Yamamoto H., Miyajima N., Toyoshima K., Yamamoto T., Yokota J. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res. 1989 Jun 1;49(11):3104–3108. [PubMed] [Google Scholar]
  182. Vlach J., Hennecke S., Alevizopoulos K., Conti D., Amati B. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J. 1996 Dec 2;15(23):6595–6604. [PMC free article] [PubMed] [Google Scholar]
  183. Wang J., Xie L. Y., Allan S., Beach D., Hannon G. J. Myc activates telomerase. Genes Dev. 1998 Jun 15;12(12):1769–1774. doi: 10.1101/gad.12.12.1769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  184. Wang T. C., Cardiff R. D., Zukerberg L., Lees E., Arnold A., Schmidt E. V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994 Jun 23;369(6482):669–671. doi: 10.1038/369669a0. [DOI] [PubMed] [Google Scholar]
  185. Watanabe G., Albanese C., Lee R. J., Reutens A., Vairo G., Henglein B., Pestell R. G. Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1. Mol Cell Biol. 1998 Jun;18(6):3212–3222. doi: 10.1128/mcb.18.6.3212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  186. Weinberg R. A. The retinoblastoma protein and cell cycle control. Cell. 1995 May 5;81(3):323–330. doi: 10.1016/0092-8674(95)90385-2. [DOI] [PubMed] [Google Scholar]
  187. Weinstat-Saslow D., Merino M. J., Manrow R. E., Lawrence J. A., Bluth R. F., Wittenbel K. D., Simpson J. F., Page D. L., Steeg P. S. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med. 1995 Dec;1(12):1257–1260. doi: 10.1038/nm1295-1257. [DOI] [PubMed] [Google Scholar]
  188. White E. Tumour biology. p53, guardian of Rb. Nature. 1994 Sep 1;371(6492):21–22. doi: 10.1038/371021a0. [DOI] [PubMed] [Google Scholar]
  189. Won K. A., Reed S. I. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J. 1996 Aug 15;15(16):4182–4193. [PMC free article] [PubMed] [Google Scholar]
  190. Woo R. A., McLure K. G., Lees-Miller S. P., Rancourt D. E., Lee P. W. DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature. 1998 Aug 13;394(6694):700–704. doi: 10.1038/29343. [DOI] [PubMed] [Google Scholar]
  191. Wu G. S., El-Diery W. S. p53 and chemosensitivity. Nat Med. 1996 Mar;2(3):255–256. doi: 10.1038/nm0396-255a. [DOI] [PubMed] [Google Scholar]
  192. Xu L., Sgroi D., Sterner C. J., Beauchamp R. L., Pinney D. M., Keel S., Ueki K., Rutter J. L., Buckler A. J., Louis D. N. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res. 1994 Oct 15;54(20):5262–5264. [PubMed] [Google Scholar]
  193. Yan Z., DeGregori J., Shohet R., Leone G., Stillman B., Nevins J. R., Williams R. S. Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3603–3608. doi: 10.1073/pnas.95.7.3603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  194. Yatabe Y., Masuda A., Koshikawa T., Nakamura S., Kuroishi T., Osada H., Takahashi T., Mitsudomi T., Takahashi T. p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res. 1998 Mar 1;58(5):1042–1047. [PubMed] [Google Scholar]
  195. Yoo G. H., Xu H. J., Brennan J. A., Westra W., Hruban R. H., Koch W., Benedict W. F., Sidransky D. Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. Cancer Res. 1994 Sep 1;54(17):4603–4606. [PubMed] [Google Scholar]
  196. Zhang T., Nanney L. B., Luongo C., Lamps L., Heppner K. J., DuBois R. N., Beauchamp R. D. Concurrent overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer Res. 1997 Jan 1;57(1):169–175. [PubMed] [Google Scholar]
  197. Zhou P., Jiang W., Weghorst C. M., Weinstein I. B. Overexpression of cyclin D1 enhances gene amplification. Cancer Res. 1996 Jan 1;56(1):36–39. [PubMed] [Google Scholar]
  198. Zhu X., Ohtsubo M., Böhmer R. M., Roberts J. M., Assoian R. K. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol. 1996 Apr;133(2):391–403. doi: 10.1083/jcb.133.2.391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  199. Zindy F., Eischen C. M., Randle D. H., Kamijo T., Cleveland J. L., Sherr C. J., Roussel M. F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998 Aug 1;12(15):2424–2433. doi: 10.1101/gad.12.15.2424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  200. Zwijsen R. M., Klompmaker R., Wientjens E. B., Kristel P. M., van der Burg B., Michalides R. J. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol Cell Biol. 1996 Jun;16(6):2554–2560. doi: 10.1128/mcb.16.6.2554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  201. Zwijsen R. M., Wientjens E., Klompmaker R., van der Sman J., Bernards R., Michalides R. J. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997 Feb 7;88(3):405–415. doi: 10.1016/s0092-8674(00)81879-6. [DOI] [PubMed] [Google Scholar]
  202. de Boer C. J., van Krieken J. H., Schuuring E., Kluin P. M. Bcl-1/cyclin D1 in malignant lymphoma. Ann Oncol. 1997;8 (Suppl 2):109–117. [PubMed] [Google Scholar]
  203. de Stanchina E., McCurrach M. E., Zindy F., Shieh S. Y., Ferbeyre G., Samuelson A. V., Prives C., Roussel M. F., Sherr C. J., Lowe S. W. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 1998 Aug 1;12(15):2434–2442. doi: 10.1101/gad.12.15.2434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  204. van Diest P. J., Michalides R. J., Jannink L., van der Valk P., Peterse H. L., de Jong J. S., Meijer C. J., Baak J. P. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol. 1997 Feb;150(2):705–711. [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES